NOVANTA INC. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; comparative period ended April 1, 2022. Amounts below are in U.S. dollars. Novanta supplies technology components and subsystems to medical and advanced industrial OEMs. Its segments are Precision Medicine and Manufacturing, Medical Solutions, and Robotics and Automation; segment renaming this quarter did not change segment composition or historical results.
Financial performance
| Metric | Q1 2023 | Prior comparable period |
|---|---|---|
| Revenue | $219.1 million | $204.2 million |
| Gross profit / margin | $97.6 million / 44.6% | $90.3 million / 44.2% |
| Operating income / margin | $26.3 million / 12.0% | $24.3 million / 11.9% |
| Net income | $18.3 million | $18.8 million |
| Basic and diluted EPS | $0.51 | $0.53 |
| Operating cash flow | $10.2 million | $11.3 million |
| Capital expenditures | $3.6 million | $6.3 million |
Revenue rose 7.3%, including $3.5 million from a prior-year acquisition; foreign exchange reduced revenue by $5.8 million. Net income and EPS declined despite higher operating income, primarily because net interest expense increased to $6.3 million from $3.1 million. The effective tax rate was 7.5%, versus 9.1%.
Segment trends
| Segment | Revenue change | Operating income | Key driver noted |
|---|---|---|---|
| Precision Medicine and Manufacturing | +10.7% to $69.5 million | $16.7 million, up from $13.4 million | Higher demand; improved factory productivity and product mix supported margin expansion. |
| Medical Solutions | +25.1% to $77.6 million | $9.8 million, up from $5.0 million | Growth in minimally invasive surgery and detection and analysis products, including acquisition contribution. |
| Robotics and Automation | -9.4% to $72.0 million | $12.0 million, down from $18.3 million | Lower microelectronics demand reduced factory utilization and margins. |
Medical products represented approximately 54% of revenue, up from 47%; advanced industrial represented 46%, down from 53%.
Balance sheet, debt and liquidity
- Cash and cash equivalents were $82.7 million at March 31, down from $100.1 million at year-end. Current assets were $404.8 million and current liabilities $142.4 million.
- Debt under the Senior Credit Facilities was $423.4 million, including $345.6 million drawn on the revolver; net debt was approximately $340.8 million. Debt matures in March 2027. The weighted-average interest rate was 5.55% in the quarter, compared with 2.49% a year earlier.
- Unused, available revolver capacity was $349.4 million. The company reported compliance with its debt covenants: leverage ratio 2.14 against a maximum of 3.50, and fixed-charge coverage 6.74 against a minimum of 1.50.
- Operating cash flow was lower year over year, mainly due to higher incentive compensation payments, partly offset by improved working-capital performance. Financing cash outflow of $25.1 million included $15.3 million of debt repayments and $9.6 million of payroll taxes on vested share awards.
Outlook, commentary and risks
- Management expects 2023 capital expenditures of approximately $25–$30 million, including a significant U.K. facility buildout for solid-state and ultrafast lasers. The filing does not provide full-year revenue or earnings guidance.
- Management said backlog at quarter-end was almost double its average pre-pandemic level, reflecting longer customer lead times, and expects lead times to shorten gradually as supply constraints ease.
- Inflation in materials, components and labor continued. Price increases and productivity initiatives have generally offset some cost pressure, but recovery may lag cost increases or be constrained by market conditions.
- The 2022 restructuring program is expected to be substantially complete by year-end 2023, with another $3.0–$3.5 million of charges anticipated. The 2020 program is expected to finish in 2023, with $0.5–$1.0 million of additional charges anticipated.
- Principal risks include cyclical industrial demand, particularly microelectronics; supply-chain disruption and component availability; inflation and higher interest rates; foreign-exchange exposure; OEM customer concentration and order timing; and medical-device regulation. The company reported no material change to its market-risk disclosures and said ordinary-course legal matters are not expected to have a material adverse effect, while noting outcomes cannot be assured.
- Management stated that operating cash flows and available revolver capacity should meet operating and capital needs for at least the next 12 months. Disclosure controls were assessed as effective, with no material change to internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether microelectronics weakness and lower Robotics and Automation utilization persist, and how they affect segment margins.
- Whether backlog converts into revenue as customer lead times normalize, and whether supply constraints or order timing change.
- How higher borrowing rates affect interest expense, debt reduction and liquidity; monitor covenant headroom and revolver usage.
- Progress and remaining costs of both restructuring programs, and whether expected savings and gross-margin improvements materialize.
- Whether planned $25–$30 million capital spending, including the U.K. buildout, is delivered on schedule and within budget.